Teva Pharmaceuticals Highlights Positive Real-World Data on AUSTEDO for Tardive Dyskinesia

Teva Pharmaceuticals recently reported positive findings from the IMPACT-TD Registry concerning the use of AUSTEDO (deutetrabenazine) and AUSTEDO XR for individuals with tardive dyskinesia (TD). The data, presented at the 2025 Neuroscience Education Institute Fall Congress from November 6-9, 2025, demonstrate substantial improvements in patients’ quality of life and reductions in the severity of involuntary movements.

Key Findings from the IMPACT-TD Registry

The interim analysis included 27 adults diagnosed with TD, all receiving treatment with AUSTEDO or AUSTEDO XR. The findings underline the transformative impact of these medications on daily living and mental health stability:

• Improvements in Daily Functioning: 77% of participants reported enhanced speech and communication abilities.
• Improved Eating Habits: 75% of participants noted better control while eating.
• Psychosocial Benefits: 65% felt a positive psychosocial impact.
• Daily Activities: 59% experienced improvements in everyday activities.
• Sleep and Pain Management: 50% reported better sleep quality and reduced pain.

Additionally, the total motor score on the Abnormal Involuntary Movement Scale (AIMS) indicated a mean decrease of -2.9, corroborating findings from earlier pivotal trials.

Mental Health Considerations

Importantly, most participants (85%) using AUSTEDO or AUSTEDO XR alongside their mental health medications observed that their mental health conditions either remained stable or improved. This statistic emphasizes the dual efficacy of AUSTEDO treatments in managing both movement disorders and underlying psychiatric conditions.

About Tardive Dyskinesia (TD)

Tardive dyskinesia is a chronic movement disorder that affects approximately 25% of individuals undergoing certain mental health treatments. The condition is characterized by involuntary, repetitive movements, which can significantly impact daily functioning and quality of life.

AUSTEDO Treatments Overview

AUSTEDO and AUSTEDO XR are both approved by the U.S. Food and Drug Administration (FDA) for treating TD and chorea associated with Huntington’s disease. These medications act as vesicular monoamine transporter 2 (VMAT2) inhibitors, making them a vital option for affected patients.

According to Teva’s Senior Medical Director, Stacy Finkbeiner, understanding the patient experience is crucial. She states, “Real-world findings are critical to informing how we innovate and improve the everyday lives of individuals living with this disease.”

The positive real-world data on AUSTEDO and AUSTEDO XR reinforces Teva Pharmaceuticals’ commitment to enhancing the quality of life for those affected by tardive dyskinesia, ultimately focusing on empowering patients toward regaining their independence.